103 related articles for article (PubMed ID: 16302003)
1. Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.
Alarcon-Vargas D; Zhang Z; Agarwal B; Challagulla K; Mani S; Kalpana GV
Oncogene; 2006 Feb; 25(5):722-34. PubMed ID: 16302003
[TBL] [Abstract][Full Text] [Related]
2. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
3. Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss.
Tsikitis M; Zhang Z; Edelman W; Zagzag D; Kalpana GV
Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12129-34. PubMed ID: 16099835
[TBL] [Abstract][Full Text] [Related]
4. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 is overexpressed in atypical teratoid/rhabdoid tumor with hSNF5/INI1 gene inactivation.
Fujisawa H; Misaki K; Takabatake Y; Hasegawa M; Yamashita J
J Neurooncol; 2005 Jun; 73(2):117-24. PubMed ID: 15981100
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5.
Zhang ZK; Davies KP; Allen J; Zhu L; Pestell RG; Zagzag D; Kalpana GV
Mol Cell Biol; 2002 Aug; 22(16):5975-88. PubMed ID: 12138206
[TBL] [Abstract][Full Text] [Related]
7. INI1 induces interferon signaling and spindle checkpoint in rhabdoid tumors.
Morozov A; Lee SJ; Zhang ZK; Cimica V; Zagzag D; Kalpana GV
Clin Cancer Res; 2007 Aug; 13(16):4721-30. PubMed ID: 17699849
[TBL] [Abstract][Full Text] [Related]
8. A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle.
Versteege I; Medjkane S; Rouillard D; Delattre O
Oncogene; 2002 Sep; 21(42):6403-12. PubMed ID: 12226744
[TBL] [Abstract][Full Text] [Related]
9. Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.
Smith ME; Cimica V; Chinni S; Jana S; Koba W; Yang Z; Fine E; Zagzag D; Montagna C; Kalpana GV
Proc Natl Acad Sci U S A; 2011 Jan; 108(1):319-24. PubMed ID: 21173237
[TBL] [Abstract][Full Text] [Related]
10. P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells.
Oruetxebarria I; Venturini F; Kekarainen T; Houweling A; Zuijderduijn LM; Mohd-Sarip A; Vries RG; Hoeben RC; Verrijzer CP
J Biol Chem; 2004 Jan; 279(5):3807-16. PubMed ID: 14604992
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors.
Das BC; Smith ME; Kalpana GV
Bioorg Med Chem Lett; 2008 Jul; 18(14):4177-80. PubMed ID: 18556204
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 4-HPR derivatives for rhabdoid tumors.
Das BC; Smith ME; Kalpana GV
Bioorg Med Chem Lett; 2008 Jul; 18(13):3805-8. PubMed ID: 18515102
[TBL] [Abstract][Full Text] [Related]
13. Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism.
Kuwahara Y; Charboneau A; Knudsen ES; Weissman BE
Cancer Res; 2010 Mar; 70(5):1854-65. PubMed ID: 20179200
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype.
Haberler C; Laggner U; Slavc I; Czech T; Ambros IM; Ambros PF; Budka H; Hainfellner JA
Am J Surg Pathol; 2006 Nov; 30(11):1462-8. PubMed ID: 17063089
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.
Cimica V; Smith ME; Zhang Z; Mathur D; Mani S; Kalpana GV
BMC Cancer; 2010 Nov; 10():634. PubMed ID: 21092078
[TBL] [Abstract][Full Text] [Related]
16. Mutation of the INI1 gene in composite rhabdoid tumor of the endometrium.
Donner LR; Wainwright LM; Zhang F; Biegel JA
Hum Pathol; 2007 Jun; 38(6):935-9. PubMed ID: 17376508
[TBL] [Abstract][Full Text] [Related]
17. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB.
Betz BL; Strobeck MW; Reisman DN; Knudsen ES; Weissman BE
Oncogene; 2002 Aug; 21(34):5193-203. PubMed ID: 12149641
[TBL] [Abstract][Full Text] [Related]
18. hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.
Rousseau-Merck MF; Versteege I; Legrand I; Couturier J; Mairal A; Delattre O; Aurias A
Cancer Res; 1999 Jul; 59(13):3152-6. PubMed ID: 10397258
[TBL] [Abstract][Full Text] [Related]
19. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.
Caramel J; Medjkane S; Quignon F; Delattre O
Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027
[TBL] [Abstract][Full Text] [Related]
20. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities.
Bourdeaut F; Fréneaux P; Thuille B; Lellouch-Tubiana A; Nicolas A; Couturier J; Pierron G; Sainte-Rose C; Bergeron C; Bouvier R; Rialland X; Laurence V; Michon J; Sastre-Garau X; Delattre O
J Pathol; 2007 Feb; 211(3):323-30. PubMed ID: 17152049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
